VIVS Projected Dividend Yield
VivoSim Labs Inc ( NASDAQ : VIVS )Organovo Holdings, Inc. is a clinical-stage biotechnology company. Co. is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. 21 YEAR PERFORMANCE RESULTS |
VIVS Dividend History Detail VIVS Dividend News VIVS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |